#USA #AffyImmune #Deyaa Adib #CAR T Therapy #Natick, Massachusetts

AffyImmune Appoints Deyaa Adib, MD as Chief Medical Officer

AffyImmune Therapeutics, a biotechnology firm specializing in cutting-edge cell therapies, has announced the appointment of Dr. Deyaa Adib as its new Chief Medical Officer (CMO). This decision underscores AffyImmune's commitment to developing its pioneering ICAM-1 targeting CAR T cell therapy designed to treat solid tumors, particularly in advanced thyroid cancers and non-small cell lung cancer.

Dr. Adib brings over 28 years of extensive experience in pharmaceutical research and development, particularly within the oncology sector. His role will involve overseeing all clinical activities at AffyImmune, including strategies for clinical development programs and leading teams in clinical operations, regulatory affairs, pharmacovigilance, and medical affairs.

Dr. Daniel Janse, the President and CEO of AffyImmune, expressed great enthusiasm about Dr. Adib joining the team, emphasizing his rich experience with late-stage clinical development and regulatory processes. This induction is expected to bolster AffyImmune's mission to meet the critical medical needs of patients dealing with severe forms of thyroid cancer and non-small cell lung cancer.

Dr. Adib has an impressive track record in the biotech and pharmaceutical industries, having been instrumental in achieving seven successful registration approvals across various solid tumors and hematologic malignancies. Prior to joining AffyImmune, he was the CMO at FibroGen, advancing their CD46 ADC program in prostate cancer and working on registration trials for pancreatic cancer.

His prior experiences also include serving as CMO for Triumvira Immunologics, where he launched two novel T cell therapy programs into clinical stages. During his tenure at Rain Therapeutics, he helped build an oncology portfolio that led to a successful IPO, and as vice president of late-stage development at Blueprint Medicines, he contributed to the development of avapritinib, now approved for gastrointestinal stromal tumors and advanced systemic mastocytosis.

Dr. Adib began his career focusing on solid tumors at Baxalta, where he worked on developing nanoliposomal irinotecan, a treatment now recognized as the global standard of care for second-line pancreatic cancer. He has also been involved in securing licensing deals for promising cancer treatments with industry partners.

His academic credentials are equally impressive. Dr. Adib received his M.B.,B.Ch. degree from Cairo University in Egypt, followed by extensive training in medical oncology. He further honed his expertise in clinical pharmacology and drug development at Tufts University in Boston. Additionally, he completed a research fellowship focused on cancer immunology and rheumatology at St. Joseph's Hospital Medical Center in New Jersey.

Expressing his excitement about joining AffyImmune, Dr. Adib stated that he is eager to lead clinical development efforts during this crucial period. He aims to push forward the current studies of AffyImmune’s innovative CAR T cell therapy, AIC100, which targets ICAM-1 for patients afflicted with advanced thyroid cancers and non-small cell lung cancers. Dr. Adib's vision is clear: to expedite the registration process and bring essential therapies to patients battling these difficult-to-treat cancers.

In summary, Dr. Deyaa Adib's appointment reflects AffyImmune Therapeutics' strategic emphasis on innovative treatment solutions for patients with significant unmet medical needs. As the company continues to develop its leading-edge CAR T therapies, Dr. Adib's leadership is expected to significantly impact the advancement and execution of breakthrough oncology solutions.

About AffyImmune Therapeutics

AffyImmune is a clinical-stage biopharmaceutical company focused on pioneering a novel ICAM-1 targeting CAR T therapy aimed at transforming the prognosis for patients with advanced solid cancers. Their lead candidate, AIC100, is currently in Phase 1 trials for treating various forms of advanced thyroid cancer. For more information, please visit their official website at www.affyimmune.com.